Alumis (NASDAQ:ALMS - Get Free Report)'s stock had its "overweight" rating restated by research analysts at Cantor Fitzgerald in a report issued on Monday, Benzinga reports.
ALMS has been the topic of several other research reports. Guggenheim started coverage on Alumis in a research note on Tuesday, July 23rd. They issued a "buy" rating and a $32.00 price target on the stock. Morgan Stanley started coverage on Alumis in a research note on Tuesday, July 23rd. They issued an "overweight" rating and a $36.00 price objective on the stock. Leerink Partnrs raised Alumis to a "strong-buy" rating in a research note on Tuesday, July 23rd. Finally, SVB Leerink started coverage on Alumis in a research note on Tuesday, July 23rd. They issued an "outperform" rating and a $29.00 price objective on the stock. Four equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat.com, Alumis has a consensus rating of "Buy" and a consensus price target of $27.50.
Check Out Our Latest Report on Alumis
Alumis Stock Up 1.6 %
ALMS stock traded up $0.20 during trading on Monday, hitting $13.00. The company had a trading volume of 135,992 shares, compared to its average volume of 149,261. Alumis has a fifty-two week low of $10.45 and a fifty-two week high of $13.53.
Institutional Investors Weigh In On Alumis
Institutional investors and hedge funds have recently made changes to their positions in the company. Millennium Management LLC bought a new stake in shares of Alumis during the second quarter worth $3,376,000. Towerview LLC bought a new stake in shares of Alumis during the second quarter worth $4,123,000. Ally Bridge Group NY LLC bought a new stake in Alumis in the second quarter valued at about $8,229,000. Yu Fan bought a new stake in Alumis in the second quarter valued at about $10,502,000. Finally, SR One Capital Management LP bought a new stake in Alumis in the second quarter valued at about $26,067,000.
Alumis Company Profile
(
Get Free Report)
Our mission is to significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. Our name, Alumis, captures our mission to enlighten immunology, and is inspired by the words "allumer"-French for illuminate-and "immunis"-Latin for the immune system. We are a clinical stage biopharmaceutical company with an initial focus on developing our two Tyrosine Kinase 2 (TYK2) inhibitors: ESK-001, a second-generation inhibitor that we are developing to maximize target inhibition and optimize tolerability, and A-005, a central nervous system (CNS) penetrant molecule.
Featured Stories
Before you consider Alumis, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Alumis wasn't on the list.
While Alumis currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
